lobaplatin in combination with methotrexate and vinblastine in patients with transitional cell carcinoma of the urinary tract—a pilot phase I/(II) study

Objective To study the efficacy and adverse reactions of lobaplatin combined with other chemotherapy drugs in the treatment of metastatic breast cancer. Methods This retrospective analysis enrolled 114 patients who were diagnosed with advanced breast cancer from January 2010 to December 2015. Lobaplatin and another chemotherapeutic agent were given to patients. The efficacy and side effects were evaluated after at least two cycles of chemotherapy. Results Therapeutic efficacy and adverse reactions could be evaluated in 112 patients with 2 complete response (CR) patients, 31 cases of partial response (PR), 52 cases of stable disease (SD) and 27 cases of progressive disease (PD). The overall response rate (ORR) was 29.5% and the disease control rate (DCR) was 75.9%. The median time to progression (TTP) was 7.7 months, and the median overall survival (OS) was expected to be 28.0 months. The main side effects were myelosuppression. Twenty five patients (21.9%) had grade 3/4 neutrophil suppression, 18 patients (15.8%) had grade 3/4 thrombocytopenia. Other toxicities included gastrointestinal reaction, peripheral neuropathy, stomatitis, hepatic dysfunction, fatigue and skin rashes, which were alleviated by symptomatic treatment. Conclusion Lobaplatin-based regimen chemotherapy for advanced metastatic breast cancer patients is effective and well tolerated.

show abstract

Lobaplatin

&NA;

2003

Drugs in R & D

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

lobaplatin in combination with methotrexate and vinblastine in patients with transitional cell carcinoma of the urinary tract—a pilot phase I/(II) study

Cited by 3 publications

References 7 publications

Lobaplatin in advanced urothelial tract tumors

Lobaplatin in advanced urothelial tract tumors

<p>Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer</p>

Lobaplatin

Contact Info

Product

Resources

About